Inogen, Inc (INGN) Product Cycle Is More Important Than EBITDA Miss - Needham & Company
Needham & Company analyst, Mike Matson, thinks there is a buying opportunity after Inogen, Inc (NASDAQ: INGN) beat consensus revenue ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)